or Try an Advanced Search...

    Small Molecule Therapies Stocks List

    Symbol Grade Name % Change
    EXEL A Exelixis, Inc. 2.77
    EWTX B Edgewise Therapeutics, Inc. 1.28
    NRIX B Nurix Therapeutics, Inc. -0.45
    IVA C Inventiva S.A. 3.38
    CTNM D Contineum Therapeutics, Inc. -0.66
    RAPT D RAPT Therapeutics, Inc. 5.19
    APTO F Aptose Biosciences, Inc. -0.08
    PRLD F Prelude Therapeutics Incorporated 3.33
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Cancer Biotechnology Treatment Of Cancer Disease Life Sciences Lymphoma Phosphoinositide 3 Kinase Inhibitor Protein Kinase Inhibitor Solid Tumors Tyrosine Kinase Acute Myeloid Leukemia Alcohol Bacterial Infections Bemcentinib Biology Blastoma Bruton's Tyrosine Kinase Cancer Therapies Clinical Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Small Molecule Therapies stocks.

    Symbol Grade Name Weight
    IDNA C iShares Genomics Immunology and Healthcare ETF 6.9
    CNCR F Loncar Cancer Immunotherapy ETF 4.78
    ARKG D ARK Genomic Revolution Multi-Sector ETF 4.29
    IBRN B iShares Neuroscience and Healthcare ETF 4.0
    FBT A First Trust Amex Biotech Index Fund 3.66
    View all Small Molecule Therapies ETFs...
    Compare ETFs
    Compare CNCR to IBRN Compare IBRN to FBT Compare IDNA to IBRN

        Small Molecule Therapies Stocks Recent News

        Date Stock Title
        Nov 1 EXEL Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
        Oct 31 EXEL Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
        Oct 31 EXEL Exelixis price target raised to $36 from $33 at Piper Sandler
        Oct 30 IVA Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
        Oct 30 EXEL Q3 2024 Exelixis Inc Earnings Call
        Oct 30 EXEL Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
        Oct 30 EXEL Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
        Oct 30 EXEL Exelixis (EXEL) Q3 2024 Earnings Call Transcript
        Oct 30 EXEL Exelixis, Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 30 EXEL Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
        Oct 29 EXEL Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
        Oct 29 EXEL Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
        Oct 29 EXEL Exelixis raises 2024 revenue guidance as Q3 beats on both lines
        Oct 29 EXEL Exelixis: Q3 Earnings Snapshot
        Oct 29 EXEL Exelixis Non-GAAP EPS of $0.47 beats by $0.05, revenue of $539.5M beats by $49.19M
        Oct 29 EXEL Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
        Oct 28 EXEL Exelixis Q3 2024 Earnings Preview
        Oct 27 PRLD Prelude Therapeutics price target lowered to $1 from $3 at Barclays
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Cancer Biotechnology Treatment Of Cancer Disease Life Sciences Lymphoma Phosphoinositide 3 Kinase Inhibitor Protein Kinase Inhibitor Solid Tumors Tyrosine Kinase Acute Myeloid Leukemia Alcohol Bacterial Infections Bemcentinib Biology Blastoma Bruton's Tyrosine Kinase Cancer Therapies Clinical Medicine
        Small Molecule Therapies

        Small molecule therapies are drugs that are designed to target specific molecules in the body, such as proteins, enzymes, or receptors. These drugs are typically small molecules that can be easily absorbed and distributed throughout the body. They are used to treat a variety of diseases, including cancer, heart disease, and neurological disorders.

        Browse All Tags